Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 2 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Synthetic peptide | 2 |
Top 5 Target | Count |
---|---|
GHR(Growth hormone receptor) | 1 |
PTH1R(Parathyroid hormone receptor) | 1 |
Target |
Mechanism PTH1R agonists [+1] |
Active Org. Amolyt Pharma SASStartup |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GHR agonists |
Active Org. Amolyt Pharma SASStartup [+1] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IGF-1R modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date07 Jun 2023 |
Sponsor / Collaborator Amolyt Pharma SASStartup |
Start Date07 Sep 2020 |
Sponsor / Collaborator Amolyt Pharma SASStartup |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Eneboparatide ( PTH1R ) | Hypoparathyroidism More | Phase 3 |
AZP-3813 ( GHR ) | Acromegaly More | Phase 1 |
AZP-3404 ( IGF-1R ) | Insulin Resistance More | Discontinued |
Bone disease peptide therapeutics (Alize Pharma III SAS) ( IGFBP2 ) | Osteoporosis More | Discontinued |